Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference Amid Progress in Neurological Therapeutics

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference. The conference is scheduled for May 20-21, 2026, with Oragenics’ presentation set for 3:15 p.m. ET on May 21. This event provides a platform for the company to update the investment community on its progress, particularly its lead candidate ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury.

The announcement comes as Oragenics prepares to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company’s proprietary intranasal delivery technology is central to its pipeline, offering a non-invasive method to target the brain directly. This platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, addressing significant unmet medical needs.

Investors will have the opportunity to engage with Oragenics through virtual one-on-one meetings during the conference. This format allows for direct dialogue about the company’s strategy, clinical timelines, and the broader implications of its technology. For those unable to attend, the press release and additional information are available in the company’s newsroom at https://ibn.fm/OGEN.

The Sidoti Micro-Cap Virtual Investor Conference is a key event for emerging growth companies, providing exposure to a wide network of investors. Oragenics’ participation underscores its commitment to advancing its pipeline and seeking support for its innovative approach to neurological care. The company’s focus on concussion and mild traumatic brain injury is particularly timely, as these conditions affect millions annually and lack approved pharmacological treatments.

Oragenics’ intranasal delivery platform differentiates it from competitors by enabling direct brain targeting, potentially improving efficacy and reducing side effects compared to systemic therapies. The company is also exploring applications in other neurological disorders, which could expand its market opportunity. With clinical trials on the horizon, the upcoming conference presentation is a critical milestone for Oragenics to communicate its value proposition to the investment community.

For more details about Oragenics, visit oragenics.com. The full press release is available at https://ibn.fm/MLd0Y.